Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : 2026 TeoTwawKi ... 2032 Darkest Interregnum -- Ignore unavailable to you. Want to Upgrade?

To: THE ANT who wrote (137681)	12/30/2017 11:49:48 PM
From: Elroy Jetson	Read Replies (1) \| Respond to of 217654

People with an elevated C-Reactive protein, not secondary to an obvious injury, need to be treated with statins to greatly reduce their risk of cardiovascular disease by reducing inflammation. There's very little evidence that treating people with normal C-Reactive protein levels reduces the risk of CVD. Ridker laid out the boundaries with this study, but most still don't understand the implications. - nejm.org - Don't be misled by the fact that Ridker still mentions cholesterol fractions to carry the slow and superstitious members of the medical community along with him. The value of farming capital is greatly overlooked by many - and that's fine by me. Paul Ridker could have been more plain spoken in his Jupiter study, except for the fact that he needed Astra-Zeneca to fund his work, so too much of the focus is on Crestor. Already generic now which is a big blow the patron. In spite of the weak evidence when used with a normal CRP I use the lowest dose of perhaps the least effective statin, pravachol, just for as potential insurance and optics. The same sort of bet I made by starting to use proscar at the age of 32.